Abstract
Women at risk of acquiring HIV have increasing antiretroviral-based options for HIV prevention, with long-acting injectable cabotegravir and oral tenofovir-based tablets approved by the US Food and Drug Administration for use as pre-exposure prophylaxis (PrEP).1–3 The dapivirine vaginal ring received a favourable scientific opinion by the European Medicines Agency in 2020, was recommended by WHO in 2021, and has been approved for PrEP use in several African countries. Limited access, risk perceptions, and personal preferences might lead to co-use of the now various forms of PrEP; however, the safety and efficacy of concurrent use has not been established.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
